Fluorouracil

Anti-metabolite

MECHANISM OF ACTION

Pyramidine analog inhibits DNA and RNA synthesis

MECHANISM OF KIDNEY INJURY

CLINICAL KIDNEY SYNDROME

myelosuppresion, hyperpigmentation, nail bnading, ocular toxicity, MI

CARDIOVASCULAR ADVERSE EFFECTS

LYTE ABNORMALITIES

RISK FACTORS

MITIGATION STRATEGIES

SUGGESTIONS

NOTES/COMMENTS

eGFR < 60 ml/min, no dose adjustment or 25% dose reduction

PHARMACOKINETICS

Molecular Weight

130

Volume of Distribution

Plasma Protein Binding

Metabolism

Bioavailability

Half-life elimination

IV bolus 8-14 mins

Time to peak

Excretion

Lung
Urine, < 10%

Dialyzable?

HD before drug administration

REF:

PATHOLOGY SLIDES:

ENTRY UPDATES:

Raad Chowdhury

United States

Sep 25, 2022

PARTNERS WITH